APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dapagliflozin Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dapagliflozin Tablets Market Outlook and Growth Opportunities 2026

29 December 2025202 pages

Choose your research edition.

Industry ResearchDapagliflozin Tablets Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Dapagliflozin Tablets Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Dapagliflozin Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dapagliflozin Tablets Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Dapagliflozin Tablets Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Dapagliflozin Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dapagliflozin Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dapagliflozin Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dapagliflozin Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dapagliflozin Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dapagliflozin Tablets market include Addii Biotech, Aetos Pharma, Casca Remedies, Fawn Incorporation, Fibovil Pharma, Jabs Biotech, Rakshit Pharmaceuticals Limited, Zydus Healthcare and AstraZeneca Pharmaceuticals (China) Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dapagliflozin Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dapagliflozin Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dapagliflozin Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dapagliflozin Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Dapagliflozin Tablets Segment by Company

Addii Biotech

Aetos Pharma

Casca Remedies

Fawn Incorporation

Fibovil Pharma

Jabs Biotech

Rakshit Pharmaceuticals Limited

Zydus Healthcare

AstraZeneca Pharmaceuticals (China) Co., Ltd.

Beijing Fuyuan Pharmaceutical Co., Ltd.

Beijing Shuanglu Pharmaceutical Co., Ltd.

Chengdu Beite Pharmaceutical Co., Ltd.

Jiangsu Hausen Pharmaceutical Group Co., Ltd.

Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.

Ningbo Minnova Tiankang Pharmaceutical Co., Ltd.

Shandong Lukang Pharmaceutical Co., Ltd.

Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.

Yiling Wanzhou International Pharmaceutical Co., Ltd.

Dapagliflozin Tablets Segment by Type

10mg

5mg

Dapagliflozin Tablets Segment by Application

Hospital

Clinic

Other

Dapagliflozin Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dapagliflozin Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dapagliflozin Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dapagliflozin Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Dapagliflozin Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dapagliflozin Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dapagliflozin Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dapagliflozin Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dapagliflozin Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dapagliflozin Tablets industry.

Chapter 3: Detailed analysis of Dapagliflozin Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dapagliflozin Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dapagliflozin Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dapagliflozin Tablets Industry Trends Table 2. Dapagliflozin Tablets Industry Drivers Table 3. Dapagliflozin Tablets Industry Opportunities and Challenges Table 4. Dapagliflozin Tablets Industry Restraints Table 5. Global Dapagliflozin Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dapagliflozin Tablets Revenue Share by Company (2021-2026) Table 7. Global Dapagliflozin Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dapagliflozin Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Dapagliflozin Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dapagliflozin Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dapagliflozin Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Dapagliflozin Tablets Company, Product Type & Application Table 13. Global Dapagliflozin Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dapagliflozin Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10mg Table 18. Significant Companies of 5mg Table 19. Global Dapagliflozin Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Dapagliflozin Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Dapagliflozin Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Dapagliflozin Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Dapagliflozin Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Dapagliflozin Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dapagliflozin Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Dapagliflozin Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Dapagliflozin Tablets Sales Value Share by Type (2021-2026) Table 28. Global Dapagliflozin Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Dapagliflozin Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Dapagliflozin Tablets Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Dapagliflozin Tablets Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Dapagliflozin Tablets Sales Volume Share by Application (2021-2026) Table 36. Global Dapagliflozin Tablets Sales Volume Share by Application (2027-2032) Table 37. Global Dapagliflozin Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Dapagliflozin Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Dapagliflozin Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Dapagliflozin Tablets Sales Value Share by Application (2021-2026) Table 41. Global Dapagliflozin Tablets Sales Value Share by Application (2027-2032) Table 42. Global Dapagliflozin Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Dapagliflozin Tablets Sales by Region (2021-2026) & (K Units) Table 44. Global Dapagliflozin Tablets Sales Market Share by Region (2021-2026) Table 45. Global Dapagliflozin Tablets Sales by Region (2027-2032) & (K Units) Table 46. Global Dapagliflozin Tablets Sales Market Share by Region (2027-2032) Table 47. Global Dapagliflozin Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Dapagliflozin Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Dapagliflozin Tablets Sales Value Share by Region (2021-2026) Table 50. Global Dapagliflozin Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Dapagliflozin Tablets Sales Value Share by Region (2027-2032) Table 52. Global Dapagliflozin Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Dapagliflozin Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Dapagliflozin Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Dapagliflozin Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Dapagliflozin Tablets Sales by Country (2021-2026) & (K Units) Table 57. Global Dapagliflozin Tablets Sales Market Share by Country (2021-2026) Table 58. Global Dapagliflozin Tablets Sales by Country (2027-2032) & (K Units) Table 59. Global Dapagliflozin Tablets Sales Market Share by Country (2027-2032) Table 60. Global Dapagliflozin Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Dapagliflozin Tablets Sales Value Market Share by Country (2021-2026) Table 62. Global Dapagliflozin Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Dapagliflozin Tablets Sales Value Market Share by Country (2027-2032) Table 64. Addii Biotech Company Information Table 65. Addii Biotech Business Overview Table 66. Addii Biotech Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Addii Biotech Dapagliflozin Tablets Product Portfolio Table 68. Addii Biotech Recent Development Table 69. Aetos Pharma Company Information Table 70. Aetos Pharma Business Overview Table 71. Aetos Pharma Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Aetos Pharma Dapagliflozin Tablets Product Portfolio Table 73. Aetos Pharma Recent Development Table 74. Casca Remedies Company Information Table 75. Casca Remedies Business Overview Table 76. Casca Remedies Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Casca Remedies Dapagliflozin Tablets Product Portfolio Table 78. Casca Remedies Recent Development Table 79. Fawn Incorporation Company Information Table 80. Fawn Incorporation Business Overview Table 81. Fawn Incorporation Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Fawn Incorporation Dapagliflozin Tablets Product Portfolio Table 83. Fawn Incorporation Recent Development Table 84. Fibovil Pharma Company Information Table 85. Fibovil Pharma Business Overview Table 86. Fibovil Pharma Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Fibovil Pharma Dapagliflozin Tablets Product Portfolio Table 88. Fibovil Pharma Recent Development Table 89. Jabs Biotech Company Information Table 90. Jabs Biotech Business Overview Table 91. Jabs Biotech Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jabs Biotech Dapagliflozin Tablets Product Portfolio Table 93. Jabs Biotech Recent Development Table 94. Rakshit Pharmaceuticals Limited Company Information Table 95. Rakshit Pharmaceuticals Limited Business Overview Table 96. Rakshit Pharmaceuticals Limited Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Rakshit Pharmaceuticals Limited Dapagliflozin Tablets Product Portfolio Table 98. Rakshit Pharmaceuticals Limited Recent Development Table 99. Zydus Healthcare Company Information Table 100. Zydus Healthcare Business Overview Table 101. Zydus Healthcare Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Zydus Healthcare Dapagliflozin Tablets Product Portfolio Table 103. Zydus Healthcare Recent Development Table 104. AstraZeneca Pharmaceuticals (China) Co., Ltd. Company Information Table 105. AstraZeneca Pharmaceuticals (China) Co., Ltd. Business Overview Table 106. AstraZeneca Pharmaceuticals (China) Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. AstraZeneca Pharmaceuticals (China) Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 108. AstraZeneca Pharmaceuticals (China) Co., Ltd. Recent Development Table 109. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information Table 110. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview Table 111. Beijing Fuyuan Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Beijing Fuyuan Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 113. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Development Table 114. Beijing Shuanglu Pharmaceutical Co., Ltd. Company Information Table 115. Beijing Shuanglu Pharmaceutical Co., Ltd. Business Overview Table 116. Beijing Shuanglu Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Beijing Shuanglu Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 118. Beijing Shuanglu Pharmaceutical Co., Ltd. Recent Development Table 119. Chengdu Beite Pharmaceutical Co., Ltd. Company Information Table 120. Chengdu Beite Pharmaceutical Co., Ltd. Business Overview Table 121. Chengdu Beite Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Chengdu Beite Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 123. Chengdu Beite Pharmaceutical Co., Ltd. Recent Development Table 124. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information Table 125. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview Table 126. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 128. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Development Table 129. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information Table 130. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview Table 131. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 133. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Development Table 134. Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Company Information Table 135. Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Business Overview Table 136. Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 138. Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Recent Development Table 139. Shandong Lukang Pharmaceutical Co., Ltd. Company Information Table 140. Shandong Lukang Pharmaceutical Co., Ltd. Business Overview Table 141. Shandong Lukang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Shandong Lukang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 143. Shandong Lukang Pharmaceutical Co., Ltd. Recent Development Table 144. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information Table 145. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview Table 146. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 148. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Development Table 149. Yiling Wanzhou International Pharmaceutical Co., Ltd. Company Information Table 150. Yiling Wanzhou International Pharmaceutical Co., Ltd. Business Overview Table 151. Yiling Wanzhou International Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Yiling Wanzhou International Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio Table 153. Yiling Wanzhou International Pharmaceutical Co., Ltd. Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Dapagliflozin Tablets Distributors List Table 157. Dapagliflozin Tablets Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Dapagliflozin Tablets Product Image Figure 2. Global Dapagliflozin Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dapagliflozin Tablets Sales (2021-2032) & (K Units) Figure 5. Global Dapagliflozin Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dapagliflozin Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10mg Image Figure 10. 5mg Image Figure 11. Global Dapagliflozin Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Dapagliflozin Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Dapagliflozin Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Dapagliflozin Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Dapagliflozin Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Dapagliflozin Tablets Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Dapagliflozin Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Dapagliflozin Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Dapagliflozin Tablets Sales Volume Share by Application (2021-2032) Figure 23. Global Dapagliflozin Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Dapagliflozin Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Dapagliflozin Tablets Sales Value Share by Application (2021-2032) Figure 26. Global Dapagliflozin Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Dapagliflozin Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Dapagliflozin Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Dapagliflozin Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 31. North America Dapagliflozin Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Dapagliflozin Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Dapagliflozin Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 37. South America Dapagliflozin Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Dapagliflozin Tablets Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Dapagliflozin Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Dapagliflozin Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Dapagliflozin Tablets Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Dapagliflozin Tablets Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 10mg
  • 5mg
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Addii Biotech
  • Aetos Pharma
  • Casca Remedies
  • Fawn Incorporation
  • Fibovil Pharma
  • Jabs Biotech
  • Rakshit Pharmaceuticals Limited
  • Zydus Healthcare
  • AstraZeneca Pharmaceuticals (China) Co., Ltd.
  • Beijing Fuyuan Pharmaceutical Co., Ltd.
  • Beijing Shuanglu Pharmaceutical Co., Ltd.
  • Chengdu Beite Pharmaceutical Co., Ltd.
  • Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  • Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  • Ningbo Minnova Tiankang Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd.
  • Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
  • Yiling Wanzhou International Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dapagliflozin Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Dapagliflozin Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Dapagliflozin Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dapagliflozin Tablets Market Dynamics
  1. 2.1 Dapagliflozin Tablets Industry Trends
  2. 2.2 Dapagliflozin Tablets Industry Drivers
  3. 2.3 Dapagliflozin Tablets Industry Opportunities and Challenges
  4. 2.4 Dapagliflozin Tablets Industry Restraints
3 Dapagliflozin Tablets Market by Company
  1. 3.1 Global Dapagliflozin Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Dapagliflozin Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Dapagliflozin Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Dapagliflozin Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Dapagliflozin Tablets Company Ranking (2024-2026)
  6. 3.6 Global Dapagliflozin Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Dapagliflozin Tablets Company Product Type and Application
  8. 3.8 Global Dapagliflozin Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dapagliflozin Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dapagliflozin Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dapagliflozin Tablets Market by Type
  1. 4.1 Dapagliflozin Tablets Type Introduction
  2. 4.1.1 10mg
  3. 4.1.2 5mg
  4. 4.2 Global Dapagliflozin Tablets Sales Volume by Type
  5. 4.2.1 Global Dapagliflozin Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Dapagliflozin Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Dapagliflozin Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Dapagliflozin Tablets Sales Value by Type
  9. 4.3.1 Global Dapagliflozin Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Dapagliflozin Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Dapagliflozin Tablets Sales Value Share by Type (2021-2032)
5 Dapagliflozin Tablets Market by Application
  1. 5.1 Dapagliflozin Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Dapagliflozin Tablets Sales Volume by Application
  6. 5.2.1 Global Dapagliflozin Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dapagliflozin Tablets Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Dapagliflozin Tablets Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Dapagliflozin Tablets Sales Value by Application
  10. 5.3.1 Global Dapagliflozin Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dapagliflozin Tablets Sales Value by Application (2021-2032)
  12. 5.3.3 Global Dapagliflozin Tablets Sales Value Share by Application (2021-2032)
6 Dapagliflozin Tablets Regional Sales and Value Analysis
  1. 6.1 Global Dapagliflozin Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dapagliflozin Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Dapagliflozin Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Dapagliflozin Tablets Sales by Region (2027-2032)
  5. 6.3 Global Dapagliflozin Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dapagliflozin Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dapagliflozin Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dapagliflozin Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Dapagliflozin Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dapagliflozin Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Dapagliflozin Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dapagliflozin Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Dapagliflozin Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dapagliflozin Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dapagliflozin Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dapagliflozin Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Dapagliflozin Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dapagliflozin Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dapagliflozin Tablets Sales Value Share by Country, 2025 VS 2032
7 Dapagliflozin Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Dapagliflozin Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dapagliflozin Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dapagliflozin Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Dapagliflozin Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Dapagliflozin Tablets Sales by Country (2027-2032)
  6. 7.4 Global Dapagliflozin Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dapagliflozin Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dapagliflozin Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dapagliflozin Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dapagliflozin Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dapagliflozin Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Addii Biotech
  2. 8.1.1 Addii Biotech Company Information
  3. 8.1.2 Addii Biotech Business Overview
  4. 8.1.3 Addii Biotech Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Addii Biotech Dapagliflozin Tablets Product Portfolio
  6. 8.1.5 Addii Biotech Recent Developments
  7. 8.2 Aetos Pharma
  8. 8.2.1 Aetos Pharma Company Information
  9. 8.2.2 Aetos Pharma Business Overview
  10. 8.2.3 Aetos Pharma Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aetos Pharma Dapagliflozin Tablets Product Portfolio
  12. 8.2.5 Aetos Pharma Recent Developments
  13. 8.3 Casca Remedies
  14. 8.3.1 Casca Remedies Company Information
  15. 8.3.2 Casca Remedies Business Overview
  16. 8.3.3 Casca Remedies Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Casca Remedies Dapagliflozin Tablets Product Portfolio
  18. 8.3.5 Casca Remedies Recent Developments
  19. 8.4 Fawn Incorporation
  20. 8.4.1 Fawn Incorporation Company Information
  21. 8.4.2 Fawn Incorporation Business Overview
  22. 8.4.3 Fawn Incorporation Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fawn Incorporation Dapagliflozin Tablets Product Portfolio
  24. 8.4.5 Fawn Incorporation Recent Developments
  25. 8.5 Fibovil Pharma
  26. 8.5.1 Fibovil Pharma Company Information
  27. 8.5.2 Fibovil Pharma Business Overview
  28. 8.5.3 Fibovil Pharma Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fibovil Pharma Dapagliflozin Tablets Product Portfolio
  30. 8.5.5 Fibovil Pharma Recent Developments
  31. 8.6 Jabs Biotech
  32. 8.6.1 Jabs Biotech Company Information
  33. 8.6.2 Jabs Biotech Business Overview
  34. 8.6.3 Jabs Biotech Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jabs Biotech Dapagliflozin Tablets Product Portfolio
  36. 8.6.5 Jabs Biotech Recent Developments
  37. 8.7 Rakshit Pharmaceuticals Limited
  38. 8.7.1 Rakshit Pharmaceuticals Limited Company Information
  39. 8.7.2 Rakshit Pharmaceuticals Limited Business Overview
  40. 8.7.3 Rakshit Pharmaceuticals Limited Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Rakshit Pharmaceuticals Limited Dapagliflozin Tablets Product Portfolio
  42. 8.7.5 Rakshit Pharmaceuticals Limited Recent Developments
  43. 8.8 Zydus Healthcare
  44. 8.8.1 Zydus Healthcare Company Information
  45. 8.8.2 Zydus Healthcare Business Overview
  46. 8.8.3 Zydus Healthcare Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Zydus Healthcare Dapagliflozin Tablets Product Portfolio
  48. 8.8.5 Zydus Healthcare Recent Developments
  49. 8.9 AstraZeneca Pharmaceuticals (China) Co., Ltd.
  50. 8.9.1 AstraZeneca Pharmaceuticals (China) Co., Ltd. Company Information
  51. 8.9.2 AstraZeneca Pharmaceuticals (China) Co., Ltd. Business Overview
  52. 8.9.3 AstraZeneca Pharmaceuticals (China) Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Pharmaceuticals (China) Co., Ltd. Dapagliflozin Tablets Product Portfolio
  54. 8.9.5 AstraZeneca Pharmaceuticals (China) Co., Ltd. Recent Developments
  55. 8.10 Beijing Fuyuan Pharmaceutical Co., Ltd.
  56. 8.10.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  60. 8.10.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Beijing Shuanglu Pharmaceutical Co., Ltd.
  62. 8.11.1 Beijing Shuanglu Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Beijing Shuanglu Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Beijing Shuanglu Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Beijing Shuanglu Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  66. 8.11.5 Beijing Shuanglu Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Chengdu Beite Pharmaceutical Co., Ltd.
  68. 8.12.1 Chengdu Beite Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Chengdu Beite Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Chengdu Beite Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chengdu Beite Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  72. 8.12.5 Chengdu Beite Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  74. 8.13.1 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information
  75. 8.13.2 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview
  76. 8.13.3 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Dapagliflozin Tablets Product Portfolio
  78. 8.13.5 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments
  79. 8.14 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  80. 8.14.1 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  84. 8.14.5 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd.
  86. 8.15.1 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  90. 8.15.5 Ningbo Minnova Tiankang Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Shandong Lukang Pharmaceutical Co., Ltd.
  92. 8.16.1 Shandong Lukang Pharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Shandong Lukang Pharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Shandong Lukang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Shandong Lukang Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  96. 8.16.5 Shandong Lukang Pharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
  98. 8.17.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  102. 8.17.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
  103. 8.18 Yiling Wanzhou International Pharmaceutical Co., Ltd.
  104. 8.18.1 Yiling Wanzhou International Pharmaceutical Co., Ltd. Company Information
  105. 8.18.2 Yiling Wanzhou International Pharmaceutical Co., Ltd. Business Overview
  106. 8.18.3 Yiling Wanzhou International Pharmaceutical Co., Ltd. Dapagliflozin Tablets Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Yiling Wanzhou International Pharmaceutical Co., Ltd. Dapagliflozin Tablets Product Portfolio
  108. 8.18.5 Yiling Wanzhou International Pharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dapagliflozin Tablets Value Chain Analysis
  2. 9.1.1 Dapagliflozin Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dapagliflozin Tablets Sales Mode & Process
  6. 9.2 Dapagliflozin Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dapagliflozin Tablets Distributors
  9. 9.2.3 Dapagliflozin Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst